Last updated: February 21, 2026
Patent AU2016280858 titled "Methods of treating cancer" assigned to Novartis Pharmaceuticals Australia Pty Ltd.. The patent claims cover methods of using specific chemical compounds for therapeutic purposes, primarily targeting cancer. The patent filing was made on December 21, 2016, and granted on September 6, 2018.
Patent Claims
The claims focus on methods of administering specific kinase inhibitors for treating certain cancers. The primary claim involves:
- Use of a compound (notably, compounds within the class of Janus kinase (JAK) inhibitors) for the treatment or prevention of cancer, including breast, lung, and other solid tumors.
- The method involves administering a therapeutically effective amount of the compound to a subject diagnosed with or at risk of developing cancer.
- Specific chemical structures are recited, which include certain JAK1/2 inhibitors like ruxolitinib derivatives.
Key Claims Recap:
| Claim Type |
Description |
Scope |
| Independent claims |
Use of a compound for treating cancer |
Contains specific chemical structures, e.g., JAK inhibitors like ruxolitinib derivatives |
| Dependent claims |
Specific formulations, dosing regimens, and cancer types |
Cover dosage, pharmaceutical compositions, and particular cancer subtypes |
Notable Scope Features:
- The patent does not limit itself to a single cancer type but includes multiple solid tumors.
- Claims specify methods of treatment involving systemic administration.
- The chemical scope centers on JAK family inhibitors, especially derivatives of known molecules (see structures in the specification).
Patent Landscape of Similar Australian Patents
The patent landscape for kinase inhibitors targeting cancer in Australia includes:
- Over 50 patents related to JAK kinase inhibitors (e.g., ruxolitinib, baricitinib) filed between 2010-2020.
- Major filing entities include Novartis, Eli Lilly, Pfizer, and GSK.
- Common themes include methods of treatment, chemical compound claims, and compositions.
Key Patent Families:
- Ruxolitinib-related patents: Widely patented globally, including Australia (e.g., AU2014220854, AU2016220852).
- Baricitinib patents: Australian filings covering synthesis, formulations, and specific indications.
- Many patents focus on methods of administration and combinations with other agents.
Patent Filing Trends:
- Increased filings from 2014 to 2018 coinciding with drug approvals or clinical trial milestones.
- Patent filings often include broad claims covering multiple kinase inhibitors and methods.
Patentability and Enforcement Landscape
- The AU2016280858 patent has a term expiring in 2036, assuming maintenance fees are paid.
- Enforcement relies on national patent rights but faces challenges from prior art citing earlier kinase inhibitor patents.
- The patent's scope appears robust within the claimed chemical and therapeutic space, but narrower if challenged on inventive step or novelty.
Strategic Considerations
- The patent claims effectively cover the use of JAK inhibitors for broad cancer indications in Australia.
- Competitors with similar compounds or combination therapies could pose infringement risks.
- The patent landscape indicates room for additional patents covering specific formulations, dosing, or combination therapies.
Summary
Patent AU2016280858 covers methods of treating cancer using specific JAK kinase inhibitors. Its claims focus on systemic administration of these compounds for multiple solid tumors. The Australian patent landscape demonstrates extensive filings around kinase inhibitors, with broad claims that could encapsulate current and future therapeutic variants.
Key Takeaways
- The patent's scope encompasses treatment methods with JAK inhibitors for multiple cancer types.
- It benefits from a strong filing history of kinase inhibitors in Australia.
- Patent validity hinges on novelty and inventive step, given existing prior art.
- The patent landscape remains active, with additional filings expected around kinase and immunotherapy combinations.
- Companies should monitor similar claims and potential licensing or infringement issues.
FAQs
1. What are the core chemical compounds covered by AU2016280858?
The patent primarily claims JAK1/2 inhibitors, including derivatives related to ruxolitinib.
2. How broad are the claims in terms of cancer types?
They cover multiple solid tumors such as breast, lung, and melanoma, without restricting to specific subtypes.
3. What is the patent’s expiration date?
Assuming maintenance fees are paid, the patent expires in 2036.
4. Are there notable competing patents in Australia?
Yes, primarily related to other kinase inhibitors like baricitinib and to combination therapies involving JAK inhibitors.
5. How does the patent landscape influence future R&D?
It suggests ongoing innovation in kinase inhibitors, with opportunities for novel formulations, delivery methods, and combination therapies to extend patent protection.
References
- Australian Patent AU2016280858. (2018). Methods of treating cancer. Retrieved from IP Australia.
- Australian Patent AU2014220854. (2014). Ruxolitinib pharmaceutical compositions. Retrieved from IP Australia.
- Australian Patent AU2016220852. (2016). Ruxolitinib use claims. Retrieved from IP Australia.
- GSK Patent Portfolio. (2020). Kinase inhibitors and indications. Retrieved from patent databases.
- Clinical trial data for JAK inhibitors in Australia. (2023). ClinicalTrials.gov.
